Download Files:
Granisetron (Hydrochloride)
SKU
HY-B0071A-100 mg
Category Reference compound
Tags 5-HT Receptor, GPCR/G Protein;Neuronal Signaling, Neurological Disease; Cancer
$50 – $120
Products Details
Product Description
– Granisetron (Hydrochloride) (BRL 43694A) is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy.
Web ID
– HY-B0071A
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C18H25ClN4O
References
– [1]Sanger GJ, Nelson DR. Selective and functional 5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron). Eur J Pharmacol. 1989 Jan 10;159(2):113-24.|[2]Maleki-Dizaji N, Eteraf-Oskouei T, Fakhrjou A, The effects of 5HT3 receptor antagonist granisetron on inflammatory parameters and angiogenesis in the air-pouch model of inflammation. Int Immunopharmacol. 2010 Sep;10(9):1010-6.|[3]Boccia RV, Gordan LN, Clark G, Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2011 Oct;19(10):1609-17.
CAS Number
– 107007-99-8
Molecular Weight
– 348.87
Compound Purity
– 99.90
SMILES
– CN1N=C(C(N[C@H]2C[C@H](N3C)CCC[C@H]3C2)=O)C4=CC=CC=C41.[H]Cl
Clinical Information
– Launched
Research Area
– Neurological Disease; Cancer
Solubility
– DMSO : 7.69 mg/mL (ultrasonic)|H2O : 100 mg/mL (ultrasonic)
Target
– 5-HT Receptor
Isoform
– 5-HT3 Receptor
Pathway
– GPCR/G Protein;Neuronal Signaling
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.